Key facts
- It has raised $19.8M across 2 recorded rounds; the latest was Early Stage VC ($19.5M) in Jun 2026.
- Notable investors include United States Department of War, CONNECT(San Diego), Digitalis Ventures, Harvard University, Wealthing VC Club — 16 tracked in total.
- Rejuvenate Bio has filed 1 Form D with the SEC, most recently Apr 2021 ($14.6M sold to 22 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Rejuvenate Bio
Funding rounds
2 roundsAbout Rejuvenate Bio
Developer of a biotechnology platform designed to increase healthspan and extend lifespan through novel gene therapies. The company offers epigenetic reprogramming technology and a one-time treatment targeting cardiovascular and metabolic diseases, enabling healthcare providers and animal health partners to restore vitality and improve longevity across species.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 15
- Website
- rejuvenatebio.com/
- Ownership
- Privately Held (backing)
Rejuvenate Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rejuvenate Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rejuvenate Bio in its N-PORT filings yet. We sweep new filings monthly.